NXTC - NextCure Inc

-

$undefined

N/A

(N/A)

NextCure Inc NasdaqGS:NXTC NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Location: 9000 Virginia Manor Road, Beltsville, MD, 20705, United States | Website: https://www.nextcure.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-36.09M

Cash

55.86M

Avg Qtr Burn

-10.3M

Short % of Float

1.54%

Insider Ownership

8.91%

Institutional Own.

48.29%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NC410 (LAIR-2 fusion)+ pembrolizumab Details
Cancer, Ovarian cancer, Colorectal cancer

Phase 1b

Update

LNCB74 (B7-H4 ADC) Details
Solid tumor/s, Cancer, Ovarian cancer, Breast cancer, Endometrial cancer

Phase 1

Data readout

NC525 (LAIR-1 mAb) Details
Solid tumor/s, Cancer, Acute myeloid leukemia

Phase 1a

Update

NC318 (S15) Details
Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma

Failed

Discontinued

Failed

Discontinued

NC762 (B7-H4 mAb) Details
Cancer, Solid tumor/s, Lung cancer, Ovarian cancer, Breast cancer

Failed

Discontinued